Stocks · News reference
Quantum BioPharma signed an agreement with Thermo Fisher to initiate a Phase 2 clinical trial for its multiple sclerosis therapy, Lucid-MS.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Thermo Fisher Scientific has introduced its new Thermo Scientific AmpSure Universal SYBR Green and Probe Master Mixes, designed to provide a cost-effective option for laboratory qPCR applications.
Thermo Fisher Scientific is issuing 800 million Swiss Francs in bonds across four tranches with maturities ranging from 3 to 12 years.
Lisa P. Britt, Senior Vice President and Chief HR Officer of Thermo Fisher Scientific, sold 2,831 shares of company stock.
Thermo Fisher Scientific announced that Executive Vice President Michael D. Shafer will retire at the end of 2026.
Filed: 2026-10-30 AccNo: 0000097745-26-000181 Size: 270 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ResMed (RMD) delivered solid first-quarter fiscal 2027 results with adjusted EPS of $2.91, up 14% year-over-year and beating consensus by 9%. Revenues grew 6% to $1.41 billion, driven by sustained demand for sleep devices and masks. Gross margins expanded 50 basis points to 62.5% from productivity gains. However, the company faced headwinds from discontinued Astral life-support device sales and the MatrixCare divestiture. RMD maintained its fiscal 2027 guidance for 5-7% core constant-currency revenue growth and $12.00-$12.25 adjusted EPS.